Immunocore Holdings Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Bahija Jallal

Chief executive officer

US$11.7m

Total compensation

CEO salary percentage	6.3%
CEO tenure	5.3yrs
CEO ownership	n/a
Management average tenure	2.2yrs
Board average tenure	4.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bahija Jallal's remuneration changed compared to Immunocore Holdings's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$12m	US$735k	-US$55m
Sep 30 2023	n/a	n/a	-US$66m
Jun 30 2023	n/a	n/a	-US$63m
Mar 31 2023	n/a	n/a	-US$52m
Dec 31 2022	US$1m	US$700k	-US$53m
Sep 30 2022	n/a	n/a	-US$62m
Jun 30 2022	n/a	n/a	-US$112m
Mar 31 2022	n/a	n/a	-US$156m
Dec 31 2021	US$35m	US$700k	-US$180m
Sep 30 2021	n/a	n/a	-US$150m
Jun 30 2021	n/a	n/a	-US$139m
Mar 31 2021	n/a	n/a	-US$116m
Dec 31 2020	US$1m	n/a	-US$101m

Compensation vs Market: Bahija's total compensation ($USD11.68M) is above average for companies of similar size in the German market ($USD2.56M).

Compensation vs Earnings: Bahija's compensation has increased whilst the company is unprofitable.

CEO

Bahija Jallal (62 yo)

5.3yrs

Tenure

US$11,678,834

Compensation

Dr. Bahija Jallal, Ph.D. serves as Director of Outpace Bio, Inc. from March 2023. She serves as Chief Executive Officer and Director of Immunocore Holdings plc (formerly known as Immunocore Holdings Limite...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Bahija Jallal	CEO & Executive Director	5.3yrs	US$11.68m	no data
Brian Di Donato	CFO & Head of Strategy	4yrs	US$3.35m	0.038% $ 1.1m
Tina Leger	Chief Human Resources Officer	2.2yrs	US$1.04m	no data
David Berman	Head of Research & Development	5.3yrs	US$4.40m	0% $ 0
John Trainer	SVP & Chief Operating Officer	less than a year	no data	no data
John Goll	SVP, Finance & Chief Accounting Officer	less than a year	no data	no data
Annelise Vuidepot	CTO and Head of Pipeline & Platform Research	no data	no data	no data
Sean Buckley	VP & Chief Information Officer	less than a year	no data	no data
Clayton Robertson	Head of Investor Relations	no data	no data	no data
Lily Hepworth	General Counsel & Company Secretary	3.3yrs	no data	no data
Elizabeth Jobes	Chief Compliance Officer	less than a year	no data	no data
Sébastien Desprez	Head of Communications	2.3yrs	no data	no data

2.2yrs

Average Tenure

55yo

Average Age

Experienced Management: 6YG's management team is considered experienced (2.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Bahija Jallal	CEO & Executive Director	5.3yrs	US$11.68m	no data
John Bell	Independent Non-Executive Chairman	9.1yrs	US$416.99k	0.027% $ 735.0k
Kristine Peterson	Independent Non-Executive Director	6.4yrs	US$389.49k	0% $ 0
Robert Perez	Independent Non-Executive Director	4.6yrs	no data	no data
Roy Steven Herbst	Independent Non-Executive Director	3.3yrs	US$386.99k	0% $ 0
Peter Ratcliffe	Independent Non-Executive Director	3.4yrs	US$384.49k	0.00066% $ 18.2k
Travis Coy	Independent Non-Executive Director	4.6yrs	no data	no data
Siddharth Kaul	Independent Non-Executive Director	1.8yrs	US$32.61k	0% $ 0

4.6yrs

Average Tenure

62.5yo

Average Age

Experienced Board: 6YG's board of directors are considered experienced (4.6 years average tenure).

Immunocore Holdings Management

Management criteria checks 2/4

Key information

Recent management updates

Insufficient new directors

Immunocore Holdings plc, Annual General Meeting, May 23, 2024

High number of new directors

High number of new directors

High number of new directors

Immunocore Holdings plc Appoints Siddharth (Sid) Kaul as A Non-Executive Member of Its Board of Directors

Recent updates

Insufficient new directors

Immunocore Holdings plc, Annual General Meeting, May 23, 2024

Full year 2023 earnings released: US$1.13 loss per share (vs US$1.09 loss in FY 2022)

Immunocore Holdings plc to Report Q4, 2023 Results on Feb 28, 2024

Immunocore Holdings plc Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2023

Immunocore Holdings plc Announces the Addition of Two New Pre-Clinical Candidates for Autoimmune Diseases to Its Pipeline

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: UK£0.04 (vs UK£0.13 in 3Q 2022)

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: UK£0.29 loss per share (vs UK£0.14 loss in 2Q 2022)

Immunocore Holdings plc to Report Q2, 2023 Results on Aug 10, 2023

First quarter 2023 earnings released: UK£0.35 loss per share (vs UK£0.37 loss in 1Q 2022)

Forecast breakeven date moved forward to 2024

Forecast breakeven date pushed back to 2025

Full year 2022 earnings released: UK£0.90 loss per share (vs UK£3.10 loss in FY 2021)

Immunocore Holdings plc Provides Revenue Guidance for the Fourth Quarter and Twelve Months Ended December 31, 2022

Immunocore Holdings plc Announces the Addition of Three New ImmTAC Product Candidates

Forecast to breakeven in 2025

Immunocore Holdings plc Presents Ovarian Cancer Expansion Data for ImmTAC® candidate IMC-C103C targeting MAGE-A4

An unknown buyer acquired a 5% stake in Immunocore Holdings plc (NasdaqGS:IMCR) from Malin Corporation plc (ISE:MLC) for approximately €150 million.

Third quarter 2022 earnings released: EPS: UK£0.13 (vs UK£0.69 loss in 3Q 2021)

High number of new directors

Second quarter 2022 earnings released

Immunocore Holdings plc to Report Q2, 2022 Results on Aug 10, 2022

High number of new directors

Immunocore Holdings plc announced that it has received $139.999988 million in funding from RTW Investments, LP, Rock Springs Capital Management LP, General Atlantic Service Company, L.P., Baker Bros. Advisors LP and another investor

Immunocore Holdings plc announced that it expects to receive $139.999988 million in funding from RTW Investments, LP, Rock Springs Capital Management LP, General Atlantic Service Company, L.P.

Immunocore Announces Dosing of First Patient with ImmTAV(R) Bispecific for HIV

High number of new directors

Immunocore Announces the Presentation of Initial Data from the Phase 1 Immtav® Trial for Chronic Hepatitis B At the EASL International Liver Congress™

Immunocore Holdings plc Appoints Siddharth (Sid) Kaul as A Non-Executive Member of Its Board of Directors

Immunocore Holdings plc Announces UK Medicines and Healthcare Products Regulatory Agency, Australian Therapeutic Goods Administration and Health Canada Approves Kimmtrak® (Tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma

Immunocore Holdings plc Presents New Data on KIMMTRAK (tebentafusp-tebn) in metastatic Cutaneous Melanoma (mCM) and metastatic Uveal Melanoma (mUM) at the 2022 American Society of Clinical Oncology Annual Meeting

Immunocore Announces Upcoming Presentations At the 2022 American Society of Clinical Oncology Annual Meeting

First quarter 2022 earnings released: UK£0.37 loss per share (vs UK£0.76 loss in 1Q 2021)

Immunocore Holdings plc, Annual General Meeting, May 12, 2022

European Commission Approves Immunocore Holdings plc's KIMMTRAK (Tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Immunocore Holdings plc Receives Positive CHMP Opinion for KIMMTRAK (Tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma

Immunocore Holdings plc Announces Approval from the United States Food and Drug Administration of KIMMTRAK for the Treatment of Unresectable or Metastatic Uveal Melanoma

Third quarter 2021 earnings released: UK£0.69 loss per share (vs UK£0.064 loss in 3Q 2020)

Immunocore Announces Publication of Phase 3 Data Comparing tebentafusp with Investigator’s Choice in the New England Journal of Medicine

Immunocore Presents Data At the European Society for Medical Oncology (Esmo) Congress 2021 Demonstrating A Reduction in Circulating Tumor DNA (ctDNA) While on Tebentafusp Is Associated with Overall Survival in the Phase 2 Clinical Trial

Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma

An unknown buyer acquired stake in Immunocore Holdings plc (NasdaqGS:IMCR) from Medigene AG (XTRA:MDG1) for $4.7 million.

Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma

Second quarter 2021 earnings released: UK£0.75 loss per share (vs UK£0.63 loss in 2Q 2020)

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age